Advanced Sleep Research GmbH — Clinical Trial Site

10 Registered trials

2 Currently recruiting

Organisation

Advanced Sleep Research GmbH

Location

Berlin, Germany

Identifier

ORG-100048573

Address

Luisenstrasse 55, Mitte, 10117, Germany

Departments

Advanced Sleep Research
Advanced Sleep Research GmbH
N/A
Not applicable
Physician
Sleep Medicine

Clinical trials at this site (10)

Search interface

Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia Recruiting

2024-516411-24-00 Insomnia Disorder 5 2026-02-25
Maridebart Cafraglutide versus Placebo in Adult Participants with Obstructive Sleep Apnea on Positive Airway Pressure Therapy (MARITIME-OSA-… Recruiting

2025-522703-14-00 "Moderate to severe obstructive sleep apnea (OSA) in ad 5 2026-02-17
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight (ATTAIN-OSA) Ended

2024-515905-25-00 Overweight or Obesity 5 2025-01-29
A Trial to Evaluate the Long-term Safety and Tolerability of TAK-861 Ended

2023-508462-15-00 Narcolepsy with Cataplexy (Narcolepsy Type 1) 10 2023-04-27
A multicenter, double-blind, randomized study to evaluate the effects of tasimelteon vs. placebo in participants with Delayed Sleep-Wake Pha… Ended

2024-516962-13-00 Delayed Sleep-Wake Phase Disorder (DSWPD) 5 2022-09-23
A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy Ended

2023-508465-32-00 Narcolepsy with Cataplexy (Narcolepsy Type 1) 5 2024-09-03
A study to learn about how elinzanetant works and how safe it is in women having sleep disturbances associated with menopause Ended

2023-504955-28-01 Sleep disturbances associated with menopause 4 2024-03-14
UNITAS Ended

2022-502483-21-00 Insomnia disorder 4 2023-07-28
A study to find out if daridorexant is safe and efficacious to treat insomnia in patients with insomnia and comorbid nocturia Ended

2022-501246-30-00 Insomnia Disorder 6 2023-03-08
A study to find out which dose of daridorexant is safe and effective to treat insomnia in children and adolescents 10 to <18 years old Ended

2024-513885-20-00 Insomnia Disorder 4 2022-12-05